China Pioneer Pharma Holdings Limited
Symbol: 1345.HK
HKSE
1.42
HKDTrhová cena dnes
13.7445
Pomer P/E
0.0000
Pomer PEG
1.67B
MRK Cap
- 0.04%
Výnos DIV
China Pioneer Pharma Holdings Limited (1345-HK) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 124.4 | 289 | 402.1 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 10 | 75 | 177.2 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 448.4 | 413.2 | 251.8 | ||||||||||||
balance-sheet.row.inventory | 0 | 417.9 | 321.1 | 294.9 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 126.2 | 186.6 | 241.5 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 1106.9 | 1134.9 | 1013.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 247.4 | 221.6 | 91.1 | ||||||||||||
balance-sheet.row.goodwill | 0 | 6.2 | 6.2 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 30.2 | 37 | 45.9 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 36.4 | 43.3 | 45.9 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 117.1 | 156.2 | 82.2 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 2.3 | 8.6 | 12 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 20.7 | -8.6 | -12 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 424 | 421 | 219.2 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 15.8 | 96.1 | ||||||||||||
balance-sheet.row.total-assets | 0 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 284.9 | 329.3 | 262 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 61.3 | 29.6 | 14 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 17.8 | 39.8 | 24.9 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 12.7 | 8 | 0.1 | ||||||||||||
Deferred Revenue Non Current | 0 | 41.4 | 43.6 | 43.6 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 0 | 143.5 | 86.2 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 70.4 | 76.3 | 69.3 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 14 | 8.7 | 0.2 | ||||||||||||
balance-sheet.row.total-liab | 0 | 513.1 | 549.2 | 417.5 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 84.1 | 59 | ||||||||||||
balance-sheet.row.common-stock | 0 | 77.4 | 77.4 | 77.6 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 634.9 | 594.8 | 444.2 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 929 | -84.1 | -59 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -634.9 | 335.6 | 386.2 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 1006.4 | 1007.8 | 908 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 11.3 | 14.7 | 3 | ||||||||||||
balance-sheet.row.total-equity | 0 | 1017.8 | 1022.5 | 911 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 117.1 | 231.2 | 259.4 | ||||||||||||
balance-sheet.row.total-debt | 0 | 74 | 37.6 | 14.1 | ||||||||||||
balance-sheet.row.net-debt | 0 | -40.4 | -176.4 | -210.8 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 235.3 | 142.6 | 52.4 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 13.6 | 12.9 | 8.4 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -193.5 | 226.3 | -147.3 | |||||||||||||
cash-flows.row.account-receivables | 0 | -168 | 66.2 | -65.3 | |||||||||||||
cash-flows.row.inventory | 0 | -25.5 | 160.2 | -82.1 | |||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-non-cash-items | 0 | 37.9 | -139.8 | 160.8 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | -26.7 | -2.4 | -20.9 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -717.2 | -2020.3 | -512.9 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 798.1 | 1976.4 | 570.5 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 7 | 71.4 | 22.1 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -13 | 8.4 | 23.9 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -1.1 | 0 | -0.1 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 26.9 | 10.4 | -2.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -25.8 | -10.3 | -2.8 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -84.7 | -129.9 | -111.9 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | -6.4 | -10.4 | -135.5 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -91 | -140.3 | -253 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | -0.3 | -0.4 | |||||||||||||
cash-flows.row.net-change-in-cash | 0 | -10.8 | 109.8 | -155.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 214 | 224.9 | 115 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 224.9 | 115 | 270.3 | |||||||||||||
cash-flows.row.operating-cash-flow | 0 | 93.3 | 242.1 | 74.2 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.free-cash-flow | 0 | 19 | 225.4 | 39.4 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1566.7 | 1556 | 1434.8 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 898.4 | 775.6 | 662.8 | ||||||||||||||
income-statement-row.row.gross-profit | 0 | 668.2 | 780.5 | 772 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 0 | 488 | 496.6 | 574.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1386.5 | 1272.1 | 1237.4 | ||||||||||||||
income-statement-row.row.interest-income | 0 | 0.6 | 10.6 | 4 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 18.9 | 13.2 | 12.7 | ||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | 0 | 133.5 | 232.2 | 187.2 | ||||||||||||||
income-statement-row.row.income-before-tax | 0 | 180.4 | 294.5 | 201.4 | ||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 51.5 | 64.5 | 60.6 | ||||||||||||||
income-statement-row.row.net-income | 0 | 145.7 | 235.3 | 142.6 |
Často kladené otázky
Čo je China Pioneer Pharma Holdings Limited (1345.HK) celkové aktíva?
China Pioneer Pharma Holdings Limited (1345.HK) celkové aktíva sú 1530905000.000.
Aký je ročný obrat podniku?
Ročné príjmy sú N/A.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.427.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -0.127.
Aká je čistá zisková marža podniku?
Čistá zisková marža je 0.093.
Aké sú celkové výnosy podniku?
Celkové príjmy sú 0.085.
Aká je China Pioneer Pharma Holdings Limited (1345.HK) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je 145718000.000.
Aký je celkový dlh firmy?
Celkový dlh je 74020000.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 488030000.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 0.000.